Anbio Biotechnology (NNNN)
NGM · Healthcare · Medical Instruments & Supplies
$15.59
-5.17%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$684.3M
Shares Outstanding
43.9M
Exchange
NGM
Currency
USD
About Anbio Biotechnology
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 23.5M | 6.7M | 8.2M | 8.6M |
| Gross Profit | 12.6M | 3.4M | 5.9M | 7.5M |
| Operating Income | 10.2M | 2.0M | 2.0M | 5.8M |
| Net Income | 10.0M | 2.3M | 2.4M | 6.4M |
| Diluted EPS | $0.07 | $0.01 | $0.05 | $nan |